Vaxxilon, a privately held company working on synthetic vaccines, has been awarded a grant of up to $1.4 million from CARB-X, with the possibility of $3.1 million more based on the achievement of milestones, to develop the first prophylactic vaccine for the prevention of carbapenem resistant Klebsiella pneumoniae (crKP).

See the Vaxxilon press release (English)

siehe Pressemitteilung (Deutsche)

See the CARB-X press release

BASEL OFFICE

Vaxxilon AG
Christoph Merian-Ring 11
4153 Reinach Switzerland

BERLIN OFFICE

Vaxxilon Deutschland GmbH
Magnusstraße 11
12489 Berlin, Germany